Merck Maintaining Its Lofty Valuation Due To Keytruda Momentum

Despite the setback that Merck faced in its Keynote-183 and Keynote-185 trials recently, its cancer drug Keytruda hasn't lost its momentum this year. To add to that, Merck's newly launched hepatitis C drug Zepatier and established HPV vaccine Gardasil have been gaining ground.